This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Paladin Labs Inc.
Paladin Labs Inc., a prominent player in the pharmaceutical industry, is headquartered in California and operates extensively across North America. Founded in 1997, the company has established itself as a leader in the development and commercialisation of innovative healthcare solutions, particularly in the areas of specialty pharmaceuticals and rare diseases. Paladin Labs is renowned for its unique portfolio of products, which includes prescription medications and over-the-counter solutions tailored to meet specific patient needs. The company’s commitment to quality and patient-centric approaches has garnered it a strong market position, marked by strategic partnerships and a robust distribution network. With a focus on enhancing patient outcomes, Paladin Labs continues to make significant strides in the healthcare landscape, solidifying its reputation as a trusted name in the industry.
DitchCarbon Score
How does Paladin Labs Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Paladin Labs Inc.'s score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Paladin Labs Inc., headquartered in Canada, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Endo Inc., which may influence its climate commitments and reporting practices. As of now, Paladin Labs Inc. has not established any documented reduction targets or climate pledges. The lack of specific emissions data suggests that the company may be in the early stages of developing its sustainability strategy or may rely on the broader corporate initiatives of its parent company, Endo Inc. Given the context of the pharmaceutical industry, it is essential for Paladin Labs Inc. to align with industry standards and best practices in carbon management. This includes potentially adopting science-based targets and engaging in initiatives such as the Carbon Disclosure Project (CDP) to enhance transparency and accountability in their climate commitments. Overall, while specific emissions data and reduction targets are currently unavailable, Paladin Labs Inc. is positioned within a corporate structure that may provide opportunities for future climate action and reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 27,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 37,395,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Paladin Labs Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
